(MENAFN- GlobeNewsWire - Nasdaq) The herpes simplex keratitis treatment market is expanding due to rising HSV infections, increased healthcare spending, telemedicine adoption, and innovative therapies. Key trends include advanced antivirals, teleophthalmology, and personalized treatments. Asia-Pacific is projected to be the fastest-growing region.Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Herpes Simplex Keratitis Treatment Market Report 2025" report has been added to ResearchAndMarkets's offering.
The herpes simplex keratitis treatment market size has grown strongly in recent years. It will grow from $4.87 billion in 2024 to $5.26 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to the rising prevalence of herpes simplex virus infections, increasing awareness regarding early diagnosis and treatment, growing healthcare expenditure, higher demand for antiviral medications, and an increase in clinical trials and research funding.
![]()
The herpes simplex keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the expanding elderly population, increased focus on ophthalmic health, rising adoption of innovative therapies, growth of healthcare infrastructure in emerging markets, and higher investment in eye disease research. Major trends in the forecast period include advancements in antiviral drug formulations, innovations in ocular drug delivery systems, integration of teleophthalmology in eye care, development of advanced diagnostic imaging techniques, and emergence of personalized treatment approaches.
The growing focus on eye health and early diagnosis is anticipated to drive the expansion of the herpes simplex keratitis treatment market in the coming years. Eye health and early diagnosis involve maintaining optimal vision and identifying eye conditions at an early stage to prevent vision loss and improve treatment outcomes. This emphasis is fueled by heightened awareness, as more individuals understand the significance of regular eye examinations in preventing severe vision issues.
Treatments for herpes simplex keratitis contribute to eye health and early diagnosis by delivering targeted antiviral therapies, which help prevent corneal damage and vision impairment. They minimize complications through timely intervention and monitoring, thereby enhancing patient outcomes and overall ocular well-being. For example, in May 2024, data from the Office for Health Improvement and Disparities, a UK government agency, indicated that vision outpatient attendances in England reached over 8.9 million in 2023, up from 8.4 million in 2022, with a rate of 15,362 per 100,000 population. This demonstrates that the increased focus on eye health and early diagnosis is promoting growth in the herpes simplex keratitis treatment market.
The increasing adoption of telemedicine is expected to further drive the growth of the herpes simplex keratitis treatment market. Telemedicine involves using digital communication technologies to provide healthcare services remotely. Its rising use is attributed to the convenience it offers, allowing patients to access medical care from home, save time, and avoid travel, thereby improving overall accessibility and efficiency.
Telemedicine supports herpes simplex keratitis treatment by enabling remote eye care consultations, making it particularly valuable for patients in underserved or rural areas. It helps reduce delays in diagnosis and treatment through timely virtual evaluations and prescription management, improving patient outcomes and convenience. For instance, in February 2023, a survey of 8,000 U.S. adults conducted by Rock Health, a nonprofit organization, found that 80% of respondents had used telemedicine at least once, marking an 8% increase from 72% in 2021. Consequently, the growing use of telemedicine is contributing to the expansion of the herpes simplex keratitis treatment market.
The rising healthcare expenditure is also expected to drive the growth of the herpes simplex keratitis treatment market. Healthcare expenditure refers to the total funds allocated to medical services, treatments, facilities, research, and public health initiatives to improve or maintain health outcomes. This increase is driven by the rising prevalence of chronic diseases, which require long-term and often costly treatments. Higher healthcare spending enhances herpes simplex keratitis treatment by providing better access to advanced medications and diagnostic technologies, making it particularly beneficial for hospitals, clinics, and specialized eye care centers.
It also improves the quality of treatment through timely interventions, research, and patient monitoring, thereby boosting overall patient outcomes and care efficiency. For example, in May 2024, the Office for National Statistics, a UK government department, reported a 5.6% increase in total healthcare expenditure in nominal terms in 2023, reflecting a 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is supporting the growth of the herpes simplex keratitis treatment market.
Major players in the herpes simplex keratitis treatment market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Bausch Health Companies Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Micro Labs Limited, Blistex Inc., Shanghai BDgene Technology Co. Ltd., Ocular Therapeutix Inc., Chimerix Inc., AiCuris Anti-infective Cures GmbH, Taj Pharmaceuticals Limited, Fera Pharmaceuticals LLC, Excision BioTherapeutics Inc., Joshi Agrochem Pharma Private Limited, Kevy's Labs Private Limited, A.S. Lifesciences Private Limited.
North America was the largest region in the herpes simplex keratitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in herpes simplex keratitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the herpes simplex keratitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value (USD) in 2025 | $5.26 Billion |
| Forecasted Market Value (USD) by 2029 | $7.05 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
Key Topics Covered:
1. Executive Summary
2. Herpes Simplex Keratitis Treatment Market Characteristics
3. Herpes Simplex Keratitis Treatment Market Trends and Strategies
4. Herpes Simplex Keratitis Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, and Covid and Recovery on the Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Herpes Simplex Keratitis Treatment Growth Analysis and Strategic Analysis Framework
5.1. Global Herpes Simplex Keratitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis of End Use Industries
5.3. Global Herpes Simplex Keratitis Treatment Market Growth Rate Analysis
5.4. Global Herpes Simplex Keratitis Treatment Historic Market Size and Growth, 2019-2024, Value ($ Billion)
5.5. Global Herpes Simplex Keratitis Treatment Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
5.6. Global Herpes Simplex Keratitis Treatment Total Addressable Market (TAM)
6. Herpes Simplex Keratitis Treatment Market Segmentation
6.1. Global Herpes Simplex Keratitis Treatment Market, Segmentation by Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Topical Antiviral Drugs Oral Antiviral Drugs Antibiotics Corticosteroids Other Therapies
6.2. Global Herpes Simplex Keratitis Treatment Market, Segmentation by Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Famciclovir Valacyclovir Acyclovir Other Drugs
6.3. Global Herpes Simplex Keratitis Treatment Market, Segmentation by Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.4. Global Herpes Simplex Keratitis Treatment Market, Segmentation by Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.5. Global Herpes Simplex Keratitis Treatment Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals Clinics Ambulatory Surgical Centers Home Care Settings
6.6. Global Herpes Simplex Keratitis Treatment Market, Sub-Segmentation of Topical Antiviral Drugs, by Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Trifluridine Ganciclovir Acyclovir
6.7. Global Herpes Simplex Keratitis Treatment Market, Sub-Segmentation of Oral Antiviral Drugs, by Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acyclovir Valacyclovir Famciclovir
6.8. Global Herpes Simplex Keratitis Treatment Market, Sub-Segmentation of Antibiotics, by Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Erythromycin Gentamicin Tobramycin
6.9. Global Herpes Simplex Keratitis Treatment Market, Sub-Segmentation of Corticosteroids, by Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prednisolone Acetate Dexamethasone Loteprednol
6.10. Global Herpes Simplex Keratitis Treatment Market, Sub-Segmentation of Other Therapies, by Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Debridement Amniotic Membrane Transplantation Corneal Transplantation
7. Herpes Simplex Keratitis Treatment Market Regional and Country Analysis
7.1. Global Herpes Simplex Keratitis Treatment Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Herpes Simplex Keratitis Treatment Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Companies Featured
Pfizer Inc. Merck & Co. Inc. Novartis AG GlaxoSmithKline plc Bausch Health Companies Inc. Aurobindo Pharma Limited Dr. Reddy's Laboratories Limited Cipla Limited Micro Labs Limited Blistex Inc. Shanghai BDgene Technology Co. Ltd. Ocular Therapeutix Inc. Chimerix Inc. AiCuris Anti-infective Cures GmbH Taj Pharmaceuticals Limited Fera Pharmaceuticals LLC Excision BioTherapeutics Inc. Joshi Agrochem Pharma Private Limited Kevy's Labs Private Limited A.S. Lifesciences Private Limited
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Herpes Simplex Keratitis Treatment Market
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
![]()
MENAFN04112025004107003653ID1110293623
Comments
No comment